IMJUDO Market Summary

Key Factors Driving IMJUDO Growth

1. Strong underlying demand in hepatocellular carcinoma (HCC): IMJUDO (tremelimumab-actl) is a CTLA-4–blocking antibody used with IMFINZI (durvalumab). Its most important commercial driver is the HIMALAYA regimen (STRIDE: a single priming dose of IMJUDO followed by regular-interval IMFINZI) in unresectable HCC. AstraZeneca reported 22% growth in IMJUDO sales during 9M 2024, specifically citing increasing HCC demand in the US as a key driver. This followed 70% growth in Q1 2024, when AstraZeneca highlighted HIMALAYA acceleration.

2. Durable long-term survival strengthens adoption in HCC: HIMALAYA provides a strong clinical foundation for continued IMJUDO use. The Phase III trial enrolled 1,171 patients and showed median overall survival of 16.43 months with STRIDE versus 13.77 months with sorafenib, with 36-month survival of 30.7% versus 20.2%. A five-year follow-up published in Hepatology in 2025 confirmed that the survival benefit was sustained, with a manageable long-term safety profile. AstraZeneca subsequently reported that approximately 20% of patients treated with STRIDE were alive at five years, supporting the regimen's durability and differentiation.

3. Expansion through first-line metastatic NSCLC: IMJUDO is also approved with IMFINZI and platinum-based chemotherapy for metastatic NSCLC without sensitising EGFR mutations or ALK genomic alterations. The POSEIDON regimen provides another major commercial source of demand, particularly in Europe. AstraZeneca reported that 9M 2024 IMJUDO growth was partly driven by NSCLC demand in Europe, demonstrating that the product's commercial contribution is not dependent solely on HCC.

4. IMJUDO benefits from the expanding IMFINZI franchise: Because IMJUDO is predominantly commercialized as a combination partner for IMFINZI, growth in the broader IMFINZI franchise can create additional opportunities for tremelimumab. IMFINZI generated $3.55 billion in H1 2026 sales, up 29% at constant exchange rates, while AstraZeneca continues to expand IMFINZI into earlier-stage lung and bladder cancers. Although IMJUDO is not automatically used in every IMFINZI indication, the growing physician familiarity and infrastructure around the IMFINZI/IMJUDO platform can support adoption of combination regimens.

5. New liver-cancer combination opportunities could expand the addressable market: AstraZeneca is pursuing next-generation IMFINZI/IMJUDO combinations in liver cancer. In the EMERALD-3 Phase III trial, adding IMFINZI + IMJUDO to lenvatinib and TACE produced a 30% reduction in the risk of disease progression or death versus TACE alone (HR 0.70; p=0.0007), with median PFS of 13.0 versus 9.8 months. AstraZeneca reported a trend toward improved overall survival in April 2026 and subsequently reported the positive PFS result in June 2026. If these findings lead to regulatory expansion and clinical adoption, they could create an additional growth channel for IMJUDO in unresectable liver cancer.

6. Increasing geographic penetration and established regulatory footprint: IMJUDO is approved in major markets for HCC and metastatic NSCLC, including the US and EU. The European Medicines Agency specifically recognizes IMJUDO + IMFINZI for first-line advanced/unresectable HCC and, with platinum chemotherapy, first-line metastatic NSCLC. Continued uptake across major markets—particularly HCC in the US and NSCLC in Europe—has already translated into meaningful sales growth.

IMJUDO Recent Developments

In June 2026, Positive results from the EMERALD-3 Phase III trial showed AstraZeneca’s IMFINZI (durvalumab) in combination with IMJUDO (tremelimumab), lenvatinib and transarterial chemoembolisation (TACE), demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolisation. Patients in the investigational arms were treated with the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), with or without lenvatinib, prior to TACE and then in combination with TACE thereafter.

“IMJUDO Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of IMJUDO for approved indication like Cancer, Liver cancer, and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Head and neck cancer, Malignant-mesothelioma, Small cell lung cancer, Solid tumours, Glioblastoma, HER2 negative breast cancer and Urogenital cancer in the 7MM. A detailed picture of IMJUDO’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the IMJUDO for approved and potential indications. The IMJUDO market report provides insights about IMJUDO’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMJUDO performance, future market assessments inclusive of the IMJUDO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMJUDO sales forecasts, along with factors driving its market.

IMJUDO Drug Summary

IMJUDO (Tremelimumab) is a human monoclonal antibody and immune checkpoint inhibitor developed by AstraZeneca that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), an immune checkpoint receptor that suppresses T-cell activation. By blocking CTLA-4, tremelimumab enhances T-cell priming and activation, thereby strengthening the immune response against tumor cells. IMJUDO is administered by intravenous infusion and is approved in combination with durvalumab (IMFINZI) for the treatment of certain patients with unresectable hepatocellular carcinoma (HCC) and metastatic non-small cell lung cancer (NSCLC), with specific indications varying by regulatory jurisdiction. Its use in combination with PD-L1 blockade provides complementary immune activation through both CTLA-4 and PD-L1 pathways, supporting its role as a dual-checkpoint immunotherapy approach in advanced solid tumors. The report provides IMJUDO’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IMJUDO Market Report

The report provides insights into:

• A comprehensive product overview including the IMJUDO MoA, description, dosage and administration, research and development activities in approved indications like Cancer, Liver cancer, and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Head and neck cancer, Malignant-mesothelioma, Small cell lung cancer, Solid tumours, Glioblastoma, HER2 negative breast cancer and Urogenital cancer.
• Elaborated details on IMJUDO regulatory milestones and other development activities have been provided in IMJUDO market report.
• The report also highlights IMJUDO‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The IMJUDO market report also covers the patents information, generic entry and impact on cost cut.
• The IMJUDO market report contains current and forecasted IMJUDO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IMJUDO market report also features the SWOT analysis with analyst views for IMJUDO in approved and potential indications.

Methodology

The IMJUDO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMJUDO Analytical Perspective by DelveInsight

• In-depth IMJUDO Market Assessment

This IMJUDO sales market forecast report provides a detailed market assessment of IMJUDO for approved indication like Cancer, Liver cancer, and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Head and neck cancer, Malignant-mesothelioma, Small cell lung cancer, Solid tumours, Glioblastoma, HER2 negative breast cancer and Urogenital cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMJUDO sales data uptil 2034.

• IMJUDO Clinical Assessment

The IMJUDO market report provides the clinical trials information of IMJUDO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IMJUDO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IMJUDO Market Potential & Revenue Forecast

• Projected market size for the IMJUDO and its key indications
• Estimated IMJUDO sales potential (IMJUDO peak sales forecasts)
• IMJUDO Pricing strategies and reimbursement landscape

IMJUDO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IMJUDO Market positioning compared to existing treatments
• IMJUDO Strengths & weaknesses relative to competitors

IMJUDO Regulatory & Commercial Milestones

• IMJUDO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IMJUDO Clinical Differentiation

• IMJUDO Efficacy & safety advantages over existing drugs
• IMJUDO Unique selling points

IMJUDO Market Report Highlights

• In the coming years, the IMJUDO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IMJUDO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMJUDO’s dominance.
• Other emerging products for Cancer, Liver cancer, and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Head and neck cancer, Malignant-mesothelioma, Small cell lung cancer, Solid tumours, Glioblastoma, HER2 negative breast cancer and Urogenital cancer are expected to give tough market competition to IMJUDO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMJUDO in approved and potential indications.
• Analyse IMJUDO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IMJUDO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMJUDO in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IMJUDO? How strong is IMJUDO’s clinical and commercial performance?
• What is IMJUDO’s clinical trial status in each individual indications such as Cancer, Liver cancer, and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Head and neck cancer, Malignant-mesothelioma, Small cell lung cancer, Solid tumours, Glioblastoma, HER2 negative breast cancer and Urogenital cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMJUDO Manufacturers?
• What are the key designations that have been granted to IMJUDO for approved and potential indications? How are they going to impact IMJUDO’s penetration in various geographies?
• What is the current and forecasted IMJUDO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IMJUDO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IMJUDO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is IMJUDO? What is the duration of therapy and what are the geographical variations in cost per patient?